Zhi-Min Shao

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Xi-Chun Hu, Jian Zhang, Bing-He Xu et al. · The Lancet Oncology · 2015 · 285 citations

Medicine, Oncology, Pharmacology +15

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Bi-Yun Wang, Jian Zhang, Jia-Lei Wang et al. · Journal of Experimental & Clinical Cancer Research · 2015 · 179 citations · Full text

Medicine, Oncology, Pharmacology +15

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Fátima Cardoso, Heather L. McArthur, Peter Schmid et al. · Annals of Oncology · 2023 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

Fan Jiang, Wenjin Yin, Jin-Song Lu et al. · Journal of Cancer Research and Clinical Oncology · 2008 · 124 citations · Full text

Medicine, Oncology, Pharmacology +14

Chemokine Decoy Receptor D6 Plays a Negative Role in Human Breast Cancer

Feng-Ying Wu, Zhou-Luo Ou, Lan-Yun Feng et al. · Molecular Cancer Research · 2008 · 84 citations

Medicine, Cancer Biology, Oncology +17